EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Understanding the financial cost of cancer clinical trial participation

Courtney P Williams iD, Luqin Deng, Nicole E Caston iD, Kathleen Gallagher iD, Rebekah Angove, Maria Pisu iD, Andres Azuero, Rebecca Arend, Gabrielle B Rocque iD

Cancer Medicine · 2024-04 · 13 (8)

DOI: 10.1002/cam4.7185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 17.04.2024. Verfasst von Courtney P Williams und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Birmingham, Alabama, USA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials as Topic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Though financial hardship is a well‐documented adverse effect of standard‐of‐care cancer treatment, little is known about out‐of‐pocket costs and their impact on patients participating in cancer clinical trials. This study explored the financial effects of cancer clinical trial participation.

Methods

This cross‐sectional analysis used survey data collected in December 2022 and May 2023 from individuals with cancer previously served by Patient Advocate Foundation, a nonprofit organization providing social needs navigation and financial assistance to US adults with a chronic illness. Surveys included questions on cancer clinical trial participation, trial‐related financial hardship, and sociodemographic data. Descriptive and bivariate analyses were conducted using Cramer's V to estimate the in‐sample magnitude of association. Associations between trial‐related financial hardship and sociodemographics were estimated using adjusted relative risks (aRR) and corresponding 95% confidence intervals (CI) from modified Poisson regression models with robust standard errors.

Results

Of 650 survey respondents, 18% ( N = 118) reported ever participating in a cancer clinical trial. Of those, 47% ( n = 55) reported financial hardship as a result of their trial participation. Respondents reporting trial‐related financial hardship were more often unemployed or disabled (58% vs. 43%; V = 0.15), Medicare enrolled (53% vs. 40%; V = 0.15), and traveled >1 h to their cancer provider (45% vs. 17%; V = 0.33) compared to respondents reporting no hardship. Respondents who experienced trial‐related financial hardship most often reported expenses from travel (reported by 71% of respondents), medical bills (58%), dining out (40%), or housing needs (40%). Modeling results indicated that respondents traveling >1 h vs. ≤30 min to their cancer provider had a 2.2× higher risk of financial hardship, even after adjusting for respondent race, income, employment, and insurance status (aRR = 2.2, 95% CI 1.3–3.8). Most respondents (53%) reported needing $200–$1000 per month to compensate for trial‐related expenses. Over half (51%) of respondents reported less willingness to participate in future clinical trials due to incurred financial hardship. Notably, of patients who did not participate in a cancer clinical trial ( n = 532), 13% declined participation due to cost.

Conclusion

Cancer clinical trial‐related financial hardship, most often stemming from travel expenses, affected almost half of trial‐enrolled patients. Interventions are needed to reduce adverse financial participation effects and potentially improve cancer clinical trial participation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials as TopicAdultAgedHumansCost of IllnessCross-Sectional StudiesHealth ExpendituresIncomeMedicareSurveys and QuestionnairesUnited States

Stichwörter der Autor:innen

cancerclinical trialscostsequityfinancial hardship

Autor:innen und Institutionen

  • University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Patient Advocate Foundation, Hampton, Virginia, USA.

ORCID-Profile: Courtney P Williams, Nicole E Caston, Kathleen Gallagher, Maria Pisu, Gabrielle B Rocque

Zitieren

APA

Williams, C. P., Deng, L., Caston, N. E., Gallagher, K., Angove, R., Pisu, M., Azuero, A., Arend, R., & Rocque, G. B. (2024). Understanding the financial cost of cancer clinical trial participation. Cancer Medicine, 13(8). https://doi.org/10.1002/cam4.7185

Vancouver

Williams CP, Deng L, Caston NE, Gallagher K, Angove R, Pisu M, et al. Understanding the financial cost of cancer clinical trial participation. Cancer Medicine. 2024;13(8). doi:10.1002/cam4.7185

BibTeX
@article{Williams2024,
  author = {Williams, Courtney P and Deng, Luqin and Caston, Nicole E and Gallagher, Kathleen and Angove, Rebekah and Pisu, Maria and Azuero, Andres and Arend, Rebecca and Rocque, Gabrielle B},
  title = {Understanding the financial cost of cancer clinical trial participation},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {8},
  doi = {10.1002/cam4.7185}
}
Kostenlos starten →